<![CDATA[Cosibelimab-ipdl Gets NCCN Category 2A Nod for Locally Advanced CSCC]]>

Дата публикации: 22-10-2026 15:00:00

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	EMA Recommends Extension of Therapeutic Indications for Cetuximab	0	11.3	14-08-2026
2	EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan	0	5	10-07-2026
3	EMA Recommends Extension of Therapeutic Indications for Epcoritamab	0	8.04	24-07-2026
4	EMA recommends extension of therapeutic indications for sacituzumab govitecan	0	11.1	18-09-2026
5	EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin	0	5	19-06-2026
6	Dr. Reddy’s gets DCGI nod for use of Zytorvi in esophageal cancer	0	6.14	21-10-2026
7	EMA Recommends Extension of Therapeutic Indications for Serplulimab	0	13.88	31-07-2026
8	<![CDATA[AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines]]>	0	16.9	20-10-2026
9	<![CDATA[Lutikizumab Meets Primary End Point in Phase 3 HS Trial]]>	0	13.47	22-10-2026
10	Identifican un mecanismo molecular que impulsa la resistencia terapéutica en el cáncer de próstata avanzado	0	7.84	20-10-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.57. Источник: www.dermatologytimes.com.